NeuBase Therapeutics, Inc.
NBSE · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $250 | $304 | $300 | $0 |
| Gross Profit | -$250 | -$304 | -$300 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $388 | $1,284 | $1,262 | $1,351 |
| G&A Expenses | $1,203 | $2,404 | $2,917 | $2,596 |
| SG&A Expenses | $1,203 | $2,404 | $2,917 | $2,596 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $18 | -$1,305 | $7 | $85 |
| Operating Expenses | $2,813 | $3,688 | $4,158 | $4,600 |
| Operating Income | -$2,813 | -$3,688 | -$4,164 | -$4,600 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$231 | $241 | $71 | $231 |
| Pre-Tax Income | -$1,821 | -$3,447 | -$4,093 | -$4,369 |
| Tax Expense | $0 | $0 | -$69 | $652 |
| Net Income | -$1,821 | -$3,447 | -$4,093 | -$4,369 |
| % Margin | – | – | – | – |
| EPS | -660.26 | -2.04 | -2.4 | -3.04 |
| % Growth | -32,265.7% | 15% | 21.1% | – |
| EPS Diluted | -660.26 | -2.04 | -2.4 | -3.04 |
| Weighted Avg Shares Out | 3 | 1,693 | 1,677 | 1,651 |
| Weighted Avg Shares Out Dil | 3 | 1,693 | 1,677 | 1,651 |
| Supplemental Information | – | – | – | – |
| Interest Income | $163 | $116 | $178 | $148 |
| Interest Expense | $0 | $1 | $2 | $2 |
| Depreciation & Amortization | $250 | $304 | $300 | $1,204 |
| EBITDA | -$1,571 | -$3,142 | -$3,784 | -$3,396 |
| % Margin | – | – | – | – |